Bradley L. Campbell was named President and Chief Executive Officer of Travere Therapeutics, Inc. As of November 6, 2026, Travere Therapeutics, Inc. has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from June 16, 2026 to September 21, 2026, naming 2 appointments and 2 departures (Form 8-K, September 21, 2026).
Who owns Travere Therapeutics, Inc.?
Travere Therapeutics, Inc. named a new President and Chief Executive Officer on Sep 21. 30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Travere Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: In · Person: Bradley L. Campbell · Role: President and Chief Executive Officer · 8-K, 2026-09-21
- · In / out: Out · Person: Sandra Calvin · 8-K, 2026-07-09
- · In / out: Out · Person: William Rote · Role: Chief Research Officer · Effective: 2027-02-17 · 8-K, 2026-06-16
Travere Therapeutics, Inc. reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-06-16 to 2026-09-21. They name 4 people, with 2 appointments and 2 departures. Every row below is cited to the filing it comes from, and this page adds each new change as Travere Therapeutics, Inc. files it.
Also on the record for Travere Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 5, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 6.1% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 1.67% of the class | 5%+ stakes | Source |
| August 12, 2026 | Stake report, Schedule 13G, by BANK OF AMERICA CORP /DE/ | 5.8% of the class | 5%+ stakes | Source |
| August 7, 2026 | Stake report, Schedule 13G, by STATE STREET CORPORATION | 4.6% of the class | 5%+ stakes | Source |
| August 6, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 7.7% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by Armistice Capital, LLC | 5.27% of the class | 5%+ stakes | Source |
| April 30, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 5.09% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 4.21% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Perceptive Advisors LLC | 4.8% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G/A, by Macquarie Group Limited | — | 5%+ stakes | Source |
| February 9, 2026 | Stake report, Schedule 13G, by STATE STREET CORPORATION | 5.3% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Travere Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Travere Therapeutics, Inc. and the records around it.
Travere Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Who owns it
Companies that share a holder
- Macquarie Group Limited also filed stake reports on 14 other companies: Artivion Inc (Feb 2026), Imax Corp (Feb 2026), Kaiser Aluminum Corp (Feb 2026)
- Perceptive Advisors LLC also filed stake reports on 57 other companies: Nautilus Biotechnology, Inc. (Nov 2026), Athira Pharma, Inc. (Oct 2026), IRulya Therapeutics Inc. (Oct 2026)
- BANK OF AMERICA CORP /DE/ also filed stake reports on 74 other companies: BlackRock 2037 Municipal Target Term Trust (Nov 2026), TRIMAS CORP (Nov 2026), PIMCO CALIFORNIA MUNICIPAL INCOME FUND (Nov 2026)
Watch Travere Therapeutics, Inc.
Get an email when Travere Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Travere Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Travere Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Travere Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 19 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-09-21 | In | President and Chief Executive Officer | 8-K, 2026-09-21 | ||
| 2026-07-09 | Out | 8-K, 2026-07-09 | |||
| 2026-06-16 | Out | Chief Research Officer | 2027-02-17 | 8-K, 2026-06-16 | |
| 2026-06-16 | In | Chief Medical Officer | 2026-07-01 | 8-K, 2026-06-16 |
Who leads Travere Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Research Officer: William Rote, departure reported, effective 2027-02-17 (filed 2026-06-16). No successor is named in these filings.
- President and Chief Executive Officer: Bradley L. Campbell, appointed (filed 2026-09-21).
- Chief Medical Officer: Jula Inrig, appointed, effective 2026-07-01 (filed 2026-06-16).
New leaders reset buying decisions — get the Full Report on Travere Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the President and Chief Executive Officer at Travere Therapeutics, Inc., with the record behind each one.
Find candidates like President and Chief Executive Officer at Travere Therapeutics, Inc.Every change, in the filing's words
Appointed: Bradley L. Campbell, President and Chief Executive Officer
Bradley L. Campbell has been named as Dr. Dube's successor with his appointment as President and Chief Executive Officer and as a member of the Board of Directors to be effective as of the Officer Resignation Date.
- (b)(c)(d) On September 21, 2026, Travere Therapeutics, Inc. (the "Company") and Eric Dube, Ph.D., mutually agreed to the timeline and terms surrounding the planned transition of Dr. Dube, who will step down from his position as the Company's President and Chief Executive Officer and as a member of the Board of Directors of the Company effective as of December 1, 2026 (the "Officer Resignation Date").
- As discussed in greater detail below, Dr. Dube has agreed to continue with the Company as Executive Advisor through February 15, 2027, to facilitate a smooth transition of responsibilities and has agreed to serve as Consultant to the Chief Executive Officer for a period following the employment transition.
- Mr. Campbell, 51, served as the President and Chief Executive Officer of Amicus Therapeutics, Inc. ("Amicus") from August 2022 until its acquisition by BioMarin Pharmaceutical Inc. in April 2026, and served as a member of Amicus' Board of Directors from June 2018 until April 2026.
- Mr. Campbell served as President and Chief Operating Officer of Amicus from January 2015 until his promotion to Chief Executive Officer in August 2022.
- He brings over 25 years of experience in the biopharmaceutical industry.
- Mr. Campbell joined Amicus in 2006 and, prior to becoming Chief Executive Officer, led the global organization responsible for the commercialization of Galafold.
Departing: Sandra Calvin
5.02(b) On July 6, 2026, Sandra Calvin, chief accounting officer (CAO) and principal accounting officer (PAO) of the Company, provided notice to the Company of her intention to retire from employment with the Company following the filing of the Company's Annual Report on Form 10-K expected in February 2027 (the "Retirement Date").
- The Company expects John Torell, CFA, CPA, the Company's Vice President, Controller, to succeed Ms. Calvin as CAO and PAO.
- The Board of Directors is expected to appoint Mr. Torell to those roles in advance of the Retirement Date to facilitate an orderly transition of responsibilities.
- Since joining the Company in 2021, Mr. Torell, has been responsible for accounting operations, financial reporting, SEC reporting, technical accounting, and internal controls over financial reporting and has served as Vice President, Controller since 2023.
- From 1997 to 2019, Mr. Torell held positions of increasing responsibility within the finance organizations at Pacific Life Insurance Company, including serving as Vice President, Controller; Vice President, Assistant Controller; and Vice President of Finance, Investment Management Division.
- Earlier in his career he was an Audit Manager with Deloitte.
- Mr. Torell is a Chartered Financial Analyst, a Certified Public Accountant and holds a B.A. in Economics-Business from the University of California, Los Angeles.
- Without limiting the foregoing, these statements are often identified by the words "on-track," "positioned," "look forward to," "will," "would," "may," "might," "believes," "anticipates," "plans," "expects," "intends," "potential," or similar expressions.
Departing: William Rote, Chief Research Officer, effective 2027-02-17
On June 12, 2026, William Rote, Ph.D., Chief Research Officer of the Company, provided notice to the Company of his intention to retire from employment with the Company, effective February 17, 2027 (the "Retirement Date"), the 10 year anniversary of his employment with the Company.
Appointed: Jula Inrig, Chief Medical Officer, effective 2026-07-01
Effective July 1, 2026, Dr. Inrig is being named Executive Vice President, Head of Research & Development and Chief Medical Officer.
- It is expected that Dr. Rote will continue to serve in his current position through the Retirement Date and will assist in the transition of his responsibilities.
- The responsibilities currently overseen by Dr. Rote are expected to be assumed by Jula Inrig, M.D., the Company's Chief Medical Officer.
- The Company expects to enter into a consulting arrangement with Dr. Rote to enable continued access to Dr. Rote following his retirement.
- Without limiting the foregoing, these statements are often identified by the words "on-track," "positioned," "look forward to," "will," "would," "may," "might," "believes," "anticipates," "plans," "expects," "intends," "potential," or similar expressions.
- Investors are referred to the full discussion of risks and uncertainties, including under the heading "Risk Factors", as included in the Company's most recent Form 10-K, Form 10-Q and other filings with the Securities and Exchange Commission.
- Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Tools for this story
Each opens in a new tab, filled in for Travere Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.